Article By:
The Fly
Monday, April 20, 2020 1:16 PM EDT
JMP Securities analyst Jason Butler reiterates an "Outperform" rating on Esperion Therapeutics, with a $191 price target after the company announced a Japanese partnership with Otsuka, for its bempedoic acid franchise.